These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 12034151)

  • 1. Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol.
    Jourdain P; Funck F; Fulla Y; Hagege A; Bellorini M; Guillard N; Loiret J; Thebault B; Desnos M
    Eur J Heart Fail; 2002 Jun; 4(3):269-76. PubMed ID: 12034151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
    Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
    J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carvedilol improves left atrial and left ventricular function and reserve in dilated cardiomyopathy after 1 year of treatment.
    Paraskevaidis I; Farmakis D; Parissis JT; Dodouras T; Filippatos G; Tsiapras D; Kremastinos DT
    J Card Fail; 2007 Mar; 13(2):108-13. PubMed ID: 17395050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dobutamine stress 99mTc-tetrofosmin quantitative gated SPECT predicts improvement of cardiac function after carvedilol treatment in patients with dilated cardiomyopathy.
    Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Tange S; Suzuki T; Kurabayashi M
    J Nucl Med; 2004 Nov; 45(11):1878-84. PubMed ID: 15534058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with beta-blockade in patients with heart failure: the Beta-Blocker Evaluation of Survival Trial (BEST).
    Eichhorn EJ; Grayburn PA; Mayer SA; St John Sutton M; Appleton C; Plehn J; Oh J; Greenberg B; DeMaria A; Frantz R; Krause-Steinrauf H
    Circulation; 2003 Nov; 108(19):2336-41. PubMed ID: 14597587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial beta-adrenergic receptor density assessed by 11C-CGP12177 PET predicts improvement of cardiac function after carvedilol treatment in patients with idiopathic dilated cardiomyopathy.
    Naya M; Tsukamoto T; Morita K; Katoh C; Nishijima K; Komatsu H; Yamada S; Kuge Y; Tamaki N; Tsutsui H
    J Nucl Med; 2009 Feb; 50(2):220-5. PubMed ID: 19164238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure.
    Pennell DJ; Ray SG; Davies G; Burgess M; Webster J; Slomka P; Atkinson P; Cleland JG
    Int J Cardiol; 2000 Feb; 72(3):265-74. PubMed ID: 10716137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
    Capomolla S; Febo O; Gnemmi M; Riccardi G; Opasich C; Caporotondi A; Mortara A; Pinna GD; Cobelli F
    Am Heart J; 2000 Apr; 139(4):596-608. PubMed ID: 10740140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
    Richards AM; Doughty R; Nicholls MG; MacMahon S; Sharpe N; Murphy J; Espiner EA; Frampton C; Yandle TG;
    J Am Coll Cardiol; 2001 Jun; 37(7):1781-7. PubMed ID: 11401111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial.
    Cleland JG; Pennell DJ; Ray SG; Coats AJ; Macfarlane PW; Murray GD; Mule JD; Vered Z; Lahiri A;
    Lancet; 2003 Jul; 362(9377):14-21. PubMed ID: 12853194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol.
    Kallistratos MS; Dritsas A; Laoutaris ID; Cokkinos DV
    Angiology; 2008; 59(3):323-8. PubMed ID: 18388105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
    Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
    Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?
    Otterstad JE; Ford I
    Eur J Heart Fail; 2002 Aug; 4(4):501-6. PubMed ID: 12167391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure.
    Maack C; Elter T; Nickenig G; LaRosee K; Crivaro M; Stäblein A; Wuttke H; Böhm M
    J Am Coll Cardiol; 2001 Oct; 38(4):939-46. PubMed ID: 11583862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure.
    Yamaji M; Tsutamoto T; Tanaka T; Kawahara C; Nishiyama K; Yamamoto T; Fujii M; Horie M
    Circ J; 2009 Jun; 73(6):1067-73. PubMed ID: 19367012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation between left ventricular contractile reserve during low dose dobutamine echocardiography and plasma concentrations of natriuretic peptides.
    Schinkel AF; Vourvouri EC; Bax JJ; Boomsma F; Bountioukos M; Rizzello V; Biagini E; Agricola E; Elhendy A; Roelandt JR; Poldermans D
    Heart; 2004 Mar; 90(3):293-6. PubMed ID: 14966050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure.
    Karabacak M; Doğan A; Tayyar Ş; Özaydın M; Erdoğan D
    Anatol J Cardiol; 2015 Apr; 15(4):271-6. PubMed ID: 25413223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of beta-blockers on left ventricular dyssynchrony and reverse remodeling in idiopathic dilated cardiomyopathy: A randomized trial of carvedilol and metoprolol.
    Kaya MG; Sarli B; Akpek M; Kaya EG; Yarlioglues M; Topsakal R; Lam YY
    Cardiol J; 2014; 21(4):434-41. PubMed ID: 24142686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.